title: Statin induced myopathy does not show up in MIBI scintigraphy.
abstract: Statin induced myopathy is the most commonly seen side effect in users of this family of drugs. Their different forms present with either creatine phosphokinase (CK) elevation or not, signs of in vivo oxidation injury or not or a combination of both. The pathogenetic background, however, still remains obscure. As MIBI, beside myocardial and tumour scintigraphy, is useful in detecting muscle metabolic abnormalities, an increased uptake of MIBI in the diseased muscular segments could be expected. We investigated seven patients (five males, two females; aged 36-56 years) with statin induced myopathy with either elevated CK, isoprostanes or muscle pains at varying combinations. MIBI whole-body imaging was done immediately, the patients still being on the respective statin. Sixteen patients (six males, 10 females) suffering from lung or breast cancer and being on statins served as controls. No uptake abnormalities in any muscular segment either in the patients or the control group were seen. Thus, MIBI scintigraphy is not useful, apparently, in diagnosing and eventually localizing statin induced myopathy. These findings indicate that MIBI scintigraphy is of no help for diagnosis and gaining further insight into statin induced myopathy.
authors.affiliation: Institute of Internal Medicine, University of Perugia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Lupattelli
authors.forename: B
authors.initials: B
authors.lastname: Palumbo
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D000069059:Atorvastatin; D001943:Breast Neoplasms / Q000000981:diagnostic imaging; D005229:Fatty Acids, Monounsaturated / Q000009:adverse effects; D005260:Female; D000077340:Fluvastatin; D006538:Heptanoic Acids / Q000009:adverse effects; D006579:Heterozygote; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000235:genetics; D007211:Indoles / Q000009:adverse effects; D008148:Lovastatin / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000000981:diagnostic imaging / Q000378:metabolism*; D009135:Muscular Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D010146:Pain; D017035:Pravastatin / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D019821:Simvastatin / Q000009:adverse effects; D017256:Technetium Tc 99m Sestamibi / Q000493:pharmacokinetics
chemical_list: D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D011725:Pyridines; D011758:Pyrroles; D019275:Radiopharmaceuticals; D000077340:Fluvastatin; D017256:Technetium Tc 99m Sestamibi; D008148:Lovastatin; D000069059:Atorvastatin; D019821:Simvastatin; C086276:cerivastatin; D017035:Pravastatin